AQUARIUS
July 6, 2024HERMES
July 6, 2024AQUARIUS
July 6, 2024HERMES
July 6, 2024AQUARIUS
July 6, 2024HERMES
July 6, 2024The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major adverse cardiovascular event (MACE) (the composite of cardiovascular [CV] death, myocardial infarction [MI], and ischemic stroke).
Read Study